Tocilizumab

Generic Name: Tocilizumab

Brand Names: Actemra, RoActemra, Tyenne, Tofidence

Drug Type: Biotech

Chemical Formula: -

CAS Number: 375823-41-9

Unique Ingredient Identifier: I031V2H011

Background: Tocilizumab is a recombinant humanized monoclonal antibody IL-6 receptor inhibitor used to treat inflammatory and autoimmune conditions. It was first described in the literature in 2003 when Chugai, a subsidiary of Roche began developing IL-6 inhibiting monoclonal antibodies. Tocilizumab was granted FDA approval on 8 January 2010 to treat a number of inflamm...

Indication: Tocilizumab is indicated to treat moderate to severe rheumatoid arthritis, giant cell arteritis, systemic sclerosis-associated interstitial lung disease, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, and cytokine release syndrome.
...

Associated Conditions: Coronavirus Disease 2019 (COVID‑19), Cytokine Release Syndrome caused by CAR-T Cell Therapy, Giant Cell Arteritis (GCA), Juvenile Chronic Polyarthritis, Moderate to Severe Rheumatoid Arthritis, Moderately to Severely Active Rheumatoid Arthritis, Polyarticular Juvenile Idiopathic Arthritis, Systemic Juvenile Idiopathic Arthritis (SJIA), Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD), Active systemic Juvenile idiopathic arthritis, Severe, active Rheumatoid arthritis

Associated Therapies: Monotherapy

Clinical Trials

A Study in Patients With Moderate to Severe Active Rheumatoid Arthritis Comparing Different Infusion Durations of RoActemra/Actemra (Tocilizumab) Treatment

Phase 2

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Tocilizumab

First Posted Date: 2011-11-09

Last Posted Date: 2015-08-17

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 47

Registration Number: NCT01468077

A Prospective Observational Study of Tocilizumab (RoActemra/Actemra) in Participants With Rheumatoid Arthritis

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Tocilizumab

First Posted Date: 2011-10-31

Last Posted Date: 2016-10-31

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 122

Registration Number: NCT01462162

A Study to Evaluate Pharmacokinetics and Safety of Tocilizumab (RoActemra/Actemra) in Participants Less Than 2 Years Old With Active Systemic Juvenile Idiopathic Arthritis (sJIA)

Phase 1

Completed

Conditions: Juvenile Idiopathic Arthritis

Interventions: Drug: Tocilizumab

First Posted Date: 2011-10-20

Last Posted Date: 2019-11-04

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 11

Registration Number: NCT01455701

Locations: 🇺🇸
Hackensack University Medical Center; Pediatric Rheumatology, Hackensack, New Jersey, United States
🇺🇸
Children's National Medical Center; Pediatric Rheumatology, Washington, District of Columbia, United States
🇺🇸
The Floating Hospital for Children at Tufts Medical Center, Boston, Massachusetts, United States

and more 17 locations

Tocilizumab for KSHV-Associated Multicentric Castleman Disease

Phase 2

Completed

Conditions: Castleman Disease
Multicentric Castleman Disease
Giant Lymph Node Hyperplasia

Interventions: Drug: Zidovudine
Drug: Tocilizumab
Drug: Valganciclovir (VGC)

First Posted Date: 2011-09-27

Last Posted Date: 2020-10-27

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 8

Registration Number: NCT01441063

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Study of Tocilizumab to Treat Polymyalgia Rheumatica

Phase 2

Completed

Conditions: Polymyalgia Rheumatica (PMR)

Interventions: Drug: Tocilizumab

First Posted Date: 2011-07-18

Last Posted Date: 2018-01-17

Lead Sponsor: Hospital for Special Surgery, New York

Target Recruit Count: 10

Registration Number: NCT01396317

Locations: 🇺🇸
Hospital for Special Surgery, New York, New York, United States

Study to Evaluate the Safety, Tolerability and Efficacy of Tocilizumab in Participants With Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Non-Biologic Disease Modifying Anti-rheumatic Drugs (DMARDs) and/or Anti-tumor Necrosis Factor (Anti-TNF) Therapy

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Tocilizumab

First Posted Date: 2011-05-27

Last Posted Date: 2017-08-02

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 110

Registration Number: NCT01362062

Locations: 🇮🇳
Excel Center, Guwahati, India
🇮🇳
Sir Gangaram Hospital, New Delhi, Delhi, India
🇮🇳
Healing Touch City Clinic, Chandigarh, India

and more 4 locations

A Study of Tocilizumab in Comparison to Etanercept in Participants With Rheumatoid Arthritis and Cardiovascular Disease Risk Factors

Phase 4

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Tocilizumab
Drug: Etanercept

First Posted Date: 2011-04-08

Last Posted Date: 2017-07-13

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 3080

Registration Number: NCT01331837

Locations: 🇺🇸
Emory Uni ; Division of Rheumatology, Atlanta, Georgia, United States
🇺🇸
Apex Medical Research, AMR, Inc., Chicago, Illinois, United States
🇺🇸
Columbus Arthritis Center, Columbus, Ohio, United States

and more 423 locations